

In the Claims

1. (Original) A method of treating a poxvirus infection, the method comprising administering to an individual an effective amount of IFN- α .
2. (Original) The method of claim 1, wherein the IFN- α is administered concurrently with a vaccinia virus vaccine.
3. (Original) The method of claim 1, wherein the individual has been vaccinated with vaccinia virus.
4. (Original) The method of claim 3, wherein the IFN- α is administered from 1 to 30 days after vaccination.
5. (Original) The method of claim 1, wherein IFN- α is administered from 1 day to 1 year before administration of a vaccinia virus vaccine.
6. (Original) The method of claim 1, further comprising administering a vaccinia virus vaccine.
7. (Original) The method of claim 1, wherein the individual has been exposed to smallpox virus, and the IFN- α is administered within 24 hours of exposure to smallpox virus.
8. (Original) The method of claim 1, wherein the individual has been exposed to smallpox virus, and the IFN- α is administered within 48 hours of exposure to smallpox virus.
9. (Original) The method of claim 1, wherein the individual has been exposed to smallpox virus, and the IFN- α is administered 72 hours to 35 days after exposure to smallpox virus.

10. (Original) A method of treating a poxvirus infection, the method comprising administering to an individual an effective amount of IFN- γ .

11. (Original) The method of claim 10, wherein the IFN- γ is administered concurrently with a vaccinia virus vaccine.

12. (Original) The method of claim 10, wherein the individual has been vaccinated with vaccinia virus.

13. (Original) The method of claim 12, wherein the IFN- γ is administered from 1 to 30 days after vaccination.

14. (Original) The method of claim 10, wherein IFN- γ is administered from 1 day to 1 year before administration of a vaccinia virus vaccine.

15. (Original) The method of claim 10, further comprising administering a vaccinia virus vaccine.

16. (Original) The method of claim 10, wherein the individual has been exposed to smallpox virus, and the IFN- γ is administered within 24 hours of exposure to smallpox virus.

17. (Original) The method of claim 10, wherein the individual has been exposed to smallpox virus, and the IFN- γ is administered within 48 hours of exposure to smallpox virus.

18. (Original) The method of claim 10, wherein the individual has been exposed to smallpox virus, and the IFN- γ is administered 72 hours to 35 days after exposure to smallpox virus.

19. (Original) A method of treating a poxvirus infection, the method comprising administering to an individual effective amounts of IFN- γ and IFN- α .

20. (Original) The method of claim 19, wherein the IFN- γ and IFN- α are administered concurrently with a vaccinia virus vaccine.

21. (Original) The method of claim 19, wherein the individual has been vaccinated with vaccinia virus.

22. (Original) The method of claim 21, wherein the IFN- γ and IFN- α are administered from 1 to 30 days after vaccination.

23. (Original) The method of claim 19, wherein the IFN- γ and IFN- α are administered from 1 day to 1 year before administration of a vaccinia virus vaccine.

24. (Original) The method of claim 19, further comprising administering a vaccinia virus vaccine.

25. (Original) The method of claim 19, wherein the individual has been exposed to smallpox virus, and the IFN- γ and IFN- α are administered within 24 hours of exposure to smallpox virus.

26. (Original) The method of claim 19, wherein the individual has been exposed to smallpox virus, and the IFN- γ and IFN- α are administered within 48 hours of exposure to smallpox virus.

27. (Original) The method of claim 19, wherein the individual has been exposed to smallpox virus, and the IFN- γ and IFN- α are administered 72 hours to 35 days after exposure to smallpox virus.

28. (Currently Amended) The method of ~~any one of claims~~ claim 1, ~~10, and 19,~~ further comprising administering an effective amount of a nucleotide analog or a nucleoside analog.

29. (Currently Amended) The method of ~~any one of claims 1-9~~ claim 1, wherein the IFN- α is a consensus interferon.

30. (Currently Amended) The method of any one of ~~claims 19-27~~ claim 19, wherein the IFN- α is a consensus interferon.

31. (New) The method of Claim 10, further comprising administering an effective amount of a nucleotide analog or a nucleoside analog.

32. (New) The method of Claim 19, further comprising administering an effective amount of a nucleotide analog or a nucleoside analog.